With lots of ASX shares to choose from on the Australian market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are outlined below. Let's see why they are bullish on them.
Image source: Getty Images
ARB Corporation Ltd (ASX: ARB)
According to a note out of Morgans, its analysts have upgraded this 4×4 accessories company's shares to a buy rating with a $22.35 price target. Morgans made the move in response to positive new vehicle sales during the month of June. This could be good news for ARB because it has a history of outperforming the market with its aftermarket sales. And while it has trimmed its earnings estimates slightly for FY 2026, it has boosted its medium-term forecasts. This partly reflects easing supply constraints for Toyota vehicles. Combined with significant share price weakness this year, Morgans thinks now could be a good time to invest. The ARB share price last traded at $18.03.
Mesoblast Ltd (ASX: MSB)
A note out of Bell Potter reveals that its analysts have put a buy rating and $4.45 price target on this biotechnology company's shares. This follows the release of a fourth-quarter update which revealed 20% quarter on quarter revenue growth. Bell Potter believes its full year performance represents an outstanding result considering its Ryoncil product was launched from a standing start in April 2025 and prior to broad reimbursement availability. The broker notes that commercial adoption has been exceptionally strong and has continued to grow as barriers to adoption have fallen away. Looking ahead, the broker expects Ryoncil's strong growth to continue. Bell Potter is also optimistic on Mesoblast's Rexlemestrocel-L product. The Mesoblast share price was fetching $2.35 at Monday's close.
Sigma Healthcare Ltd (ASX: SIG)
Analysts at Macquarie have retained their outperform rating and $3.50 price target on this pharmacy chain operator's shares. According to the note, the broker has been looking at the consumer sector and continues to rate Sigma Healthcare as a preferred pick. Macquarie is bullish on the company due to its attractive valuation and exposure to structural tailwinds that are supporting the pharmacy industry. The Sigma Healthcare share price last traded at $2.92.
